Theriva Biologics Inc

The 2020 Plan Increase Proposal seeks stockholder approval to amend the Company’s 2020 Stock Incentive Plan to increase the aggregate share pool from 4,500,000 to 6,500,000 shares, effective upon a strategic transaction or January 1, 2027. Management is seeking this approval because it says the current available share reserve (1,929,841 as of the record date) is insufficient to meet hiring, retention and incentive needs through the next 12 months and beyond, particularly given the Company’s reliance on equity awards instead of cash to conserve liquidity. The proposal also serves to satisfy NYSE American rules and to preserve the ability to grant incentive stock options under Section 422 of the Code. The Board’s rationale is two-fold: operational (to maintain a competitive equity compensation program that supports recruiting and retention) and technical/regulatory (to comply with exchange and tax qualification requirements). The Company discloses metrics (burn rate, dilution, overhang) to characterize historical usage and dilution, and notes that without approval it would need to rely on limited remaining shares or grant inducement awards outside the plan, which may be less attractive or efficient. Approval will increase potential dilution and overhang and could be dilutive to existing holders if awards are granted and exercised; management frames that trade-off as necessary to secure talent while managing annual grant pacing. The Board unanimously recommends a FOR vote, asserting this increase is necessary to align employee incentives to stockholder value and to preserve flexibility for strategic transactions or hiring needs. For a sophisticated analyst, key considerations include projected hiring needs, expected burn rate going forward, potential dilution and timing of the effective date, and whether the increased pool is sized proportionately to the Company’s hiring and compensation plans and capital constraints.

Proposal 4 requests shareholder approval to amend the Company’s Articles of Incorporation to increase authorized common shares from 350 million to 450 million, with the Board retaining discretion to file the amendment within one year should it determine it is advisable. Management frames the increase as necessary to preserve flexibility for equity financings, strategic transactions, equity incentive plan issuances and to meet NYSE American stockholders’ equity requirements; the Board asserts the additional authorized shares would allow timely action on financing or strategic opportunities without the delay of a special meeting. The filing discloses the immediate dilutive risk only occurs when shares are issued, but explicitly warns of potential dilution to earnings per share, book value, and voting power if shares are issued at prices that create dilution. The disclosure also addresses potential anti-takeover effects—acknowledging that increasing the pool of authorized but unissued shares could be used defensively to dilute bidders or perpetuate management, although Board states that is not the purpose. The proposal is primarily governance and capital-structure focused rather than compensatory, and its approval would give management and the Board broad discretion over future issuances subject to applicable law and exchange rules. Key considerations for an analyst include the Company’s near-term financing needs and plans, the extent to which the increased authorization is likely to be used for routine compensation versus dilutive financing or strategic transactions, any timing (Board retains one-year window to effect amendment), and whether additional governance protections (pre-emptive rights, supermajority approvals) are in place—none of which are proposed here. The Board unanimously recommends a FOR vote, arguing that limited authorized shares could impede the Company’s ability to raise capital or pursue transactions.

The Warrant Exercise Proposal asks shareholders to permit issuance of up to 16,184,560 shares upon exercise of New Warrants issued as inducements to institutional warrant holders who immediately exercised existing warrants at a reduced price in October 2025. Management entered into an Inducement Agreement and issued the New Warrants (200% of the exercised shares) at a $0.54 exercise price; NYSE American Section 713(a) requires shareholder approval before such warrants can be exercised because the transaction involves issuance equal to 20% or more of outstanding stock at a price potentially below the exchange’s Minimum Price. The company has already filed and obtained effectiveness of a resale registration statement, and the Inducement Agreement requires repeated shareholder meetings until approval is obtained or the New Warrants expire. Management says approval would enable up to approximately $8.7 million in gross proceeds if the New Warrants are exercised for cash, providing important liquidity for operations; if not approved, the company cannot permit exercise and must continue to convene meetings at additional cost. The proposal also contemplates adjustments and limitations (anti‑ownership‑limit provisions at 4.99%/9.99%), cashless exercise in absence of an effective registration statement, and broad change-of-control redemption protections for holders. Board recommends FOR, but stockholders should weigh dilution and potential downward pressure on share price from issuance and resale versus the near-term financing benefit and the contractual obligations the company took on when it entered the Inducement Agreement.

The Adjournment Proposal asks shareholders to authorize the proxies to adjourn or postpone the Annual Meeting if there are insufficient votes to approve Proposals 3, 4 or 5, enabling the Company to solicit additional proxies. Management seeks a routine procedural authority that is commonly used to avoid holding up critical proposals where a quorum or requisite vote is not achieved, and to permit additional outreach to holders who may be undecided or who failed to return voting instructions. The Board’s rationale is pragmatic: three materially important non-routine proposals (equity plan increase, authorized share increase, and warrant exercise) could fail due to lack of votes or broker non-votes; adjournment authority provides flexibility to re-solicit and avoid the costs and delay of reconvening multiple special meetings under the Inducement Agreement. Approval gives the Board discretion to pause meeting action and re-open solicitation without prejudice, but also could be used strategically to delay final outcomes. From a governance perspective, investors should evaluate the company’s likelihood of needing additional solicitation time (e.g., presence of broker non-votes, prior unsuccessful special meetings) and weigh the operational benefit of avoiding an immediate defeat against the possibility of management using adjournment tactically. The Board unanimously recommends a FOR vote; given the company’s prior unsuccessful special meetings to satisfy the Warrant Exercise approval, the practical need for adjournment authority appears well supported.